Compare CCSI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | STRO |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.6M | 491.0M |
| IPO Year | 2022 | N/A |
| Metric | CCSI | STRO |
|---|---|---|
| Price | $35.03 | $29.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $37.50 | $31.33 |
| AVG Volume (30 Days) | 144.7K | ★ 252.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $349,696,000.00 | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $27.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.42 | $0.67 |
| 52 Week High | $37.30 | $43.85 |
| Indicator | CCSI | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 60.69 | 51.94 |
| Support Level | $25.76 | $23.53 |
| Resistance Level | $36.36 | $30.94 |
| Average True Range (ATR) | 1.62 | 2.69 |
| MACD | -0.18 | 0.51 |
| Stochastic Oscillator | 75.67 | 70.12 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.